Sponsors
The bill strengthens tools to reduce illicit fentanyl analog supply and speed prosecutions — improving public safety — but does so by broadly criminalizing large classes of compounds, increasing risks of over-criminalization, impeding legitimate research, and imposing economic and administrative costs.
General public: Fewer illicit fentanyl analogs on the street because the law broadly schedules fentanyl-related classes (including salts/isomers/preparations) and tightens penalties, making designer opioids harder to circulate.
Law enforcement and federal prosecutors: Clearer legal authority and reduced proof requirements let agencies seize, charge, and prosecute distributors of fentanyl-related substances more quickly and straightforwardly.
Border communities and the broader public: Stronger import/export penalties create a greater deterrent to international shipments of fentanyl-related substances, which may reduce supply coming into U.S. ports and borders.
Researchers, pharmaceutical developers, and patients: Broad Schedule I placement will restrict legitimate research on many fentanyl-related compounds and likely slow development and clinical testing of new analgesics, delaying patient access to potential therapies.
Low-income individuals, racial and ethnic minorities, and defendants: Removing statutory safeguards and broadly categorizing fentanyl-related substances increases the risk of over-criminalization, harsher sentences, and uneven prosecutorial impact on marginalized communities.
Chemical manufacturers, importers/exporters, and small businesses: Structurally broad scheduling and easier import/export prosecutions create enforcement uncertainty, risk criminalizing intermediates or marginally related compounds, and could slow legitimate trade and operations.
Based on analysis of 4 sections of legislative text.
Defines and places a broad class of fentanyl-related substances into Schedule I and treats them as analogues for certain criminal and import/export penalties without proof under the analogue statute.
Introduced February 6, 2025 by Scott Fitzgerald · Last progress February 6, 2025
Creates a broad, structural definition of “fentanyl-related substances” and places those substances into Schedule I of the Controlled Substances Act unless specifically exempted or already scheduled. It also treats any such fentanyl-related substance as a statutory analogue of a listed fentanyl compound for certain criminal, sentencing, and import/export provisions, without requiring prosecutors to prove the usual statutory definition of an analogue. The change takes effect one day after enactment. The text expands criminal liability and penalties for possession, distribution, and import/export of many fentanyl variants, and it may affect law enforcement, prosecutors, researchers, medical providers, and border enforcement activities immediately on enactment.